Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Technical hurdles in a pilot clinical trial of combined B7-2 and GM-CSF immunogene therapy for glioblastomas and melanomas

20 Apr 2006

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glioma Diagnosis and Treatment
Share to Immunotherapy and Immune Responses
Share to Toxin Mechanisms and Immunotoxins

Source

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Identifiers

PMID: 16718522
DOI: 10.1007/s11060-005-9058-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Technical hurdles in a pilot clinical trial of combined B7-2 and GM-CSF immunogene therapy for glioblastomas and melanomasPMID 16718522Read ↗

CAR T cell therapy for glioblastoma: A review of the first decade of clinical trialsSemantic proximity Read ↗

Molecular therapy for melanoma: useful and not useful targets.Semantic proximity Read ↗

Adoptive transfer of IL13Rα2-specific T cells for the treatment of glioblastoma: building on clinical achievements with second-generation CARsSemantic proximity Read ↗

Engineered cells as glioblastoma therapeuticsSemantic proximity Read ↗

Therapeutic cancer vaccine survives biotech bustSemantic proximity Read ↗

TCR-T cell therapy: current development approaches, preclinical evaluation, and perspectives on regulatory challengesSemantic proximity Read ↗

Autologous Anti-GD2 CAR T Cells Efficiently Target Primary Human GlioblastomaSemantic proximity Read ↗

Shortened ex vivo manufacturing time of EGFRvIII-specific chimeric antigen receptor (CAR) T cells reduces immune exhaustion and enhances antiglioma therapeutic functionSemantic proximity Read ↗

Tumour suppression: Putting on the brakesSemantic proximity Read ↗

Technical advancement in regulatory T cell isolation and characterization using CD127 expression in patients with malignant glioma treated with autologous dendritic cell vaccinationSemantic proximity Read ↗

The Epidermal Growth Factor Variant III Peptide Vaccine for Treatment of Malignant GliomasSemantic proximity Read ↗

Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.